- About MEDx
- Technology Centers
- Pharma Solutions
-
Products
IHC-Based AssaysPCR-Based AssaysNGS-Based AssaysMore AssaysCustomized AssaysSolid Tumor - Pan-Solid Tumors - Lung Cancer - Stomach Cancer - Breast Cancer - Soft Tissue Sarcoma - Other Cancer Types
Solid TumorBlood CancerRUO ProductsIVD/CDx Products - Clinical Testing
- Quality Systems
- Events
- Contact Us
Abnormally high expression of programmed death-ligand 1 (PD-L1) on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, since PD-L1 binding to its receptor, programmed death-1 (PD1) on the surface of T cells, activates downstream signaling pathways and inhibits T cell activation. PD-L1 expression in cancer tissues by immunohistochemistry (IHC) is the first predictive biomarker for checkpoint blocking immunotherapy. Immune checkpoint inhibitors of anti-PD-1/PD-L1 antibodies are able to overcome the immune suppression activity by blocking the combination of PD-L1 and PD-1 and then have recently become a hot topic in cancer immunotherapy. The PD-1/PD-L1 inhibitor’s efficacy can be predicted to a certain extent by detecting PD-L1 expression in the cancer tissues. MEDx Translational Medicine has developed a PD-L1 IHC detection kit that has been used to assay the expression level of PD-L1 protein in the tumor samples.
● Suitable Instrument：Leica Bond MAX
● Sample Requirements: FFPE tissues
● Extensive Indications: Solid tumors, mainly nsNSCLC
● Excellent Performance:97.7% consistence with FDA-approved PD-L1 CDx Kit
AI-based pathology
● Companion Diagnostics:Immune checkpoint inhibitors（OPDIVO, et al）
● Broad Applications:Covering multiple indications（NSCLC, GC, EC,TNBC et al）
● High Compatibility:Compatible with most mainstream automatic IHC platforms
If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.
1. Customized or bulk orders of IVD/CDx products.
2. Get a quote for IVD/CDx products
3. Become our distributor
4. Get customized pharmaceutical service solutions
5.Learn more about our technology and R&D
